MindWalk Holdings (HYFT) Operating Margin (2020 - 2026)
MindWalk Holdings (HYFT) reported Operating Margin of 0.6% for Q1 2026, up 91066.0% year-over-year from N/an in Q1 2025, and up 100.0% quarter-over-quarter from 98302618816.68% in Q4 2025.
MindWalk Holdings (HYFT) Operating Margin (2020 - 2026) Analysis & Trends
MindWalk Holdings (HYFT) has 7 years of Operating Margin data on file, last reported at 0.6% in Q1 2026.
- Operating Margin for Q1 2026 came in at 0.6%, up 91066.0% year-over-year; the trailing twelve-month figure through Jan 2026 was 97307.67% (down 9691470.0% YoY), and the FY2025 annual result was 136867.86%, down 13673514.0% from the prior year.
- Operating Margin grew to 0.6% in Q1 2026 per HYFT's latest filing, from 98302618816.68% in the prior quarter.
- Over five years, Operating Margin peaked at 0.0% in Q4 2022 and troughed at 98302618816.68% in Q4 2025.
- A 5-year average of 5782512390.86% and a median of 88.57% in 2023 frame the typical range for Operating Margin.
- The sharpest annual moves came in 2023 and 2025: Operating Margin surged 8936107 bps in 2023, then plunged 2000000000 bps in 2025.
- A 5-year view of Operating Margin shows it stood at 0.0% in 2022, then sank by 32568507 bps to 49.15% in 2023, then jumped by 100 bps to 0.0% in 2024, then slumped by 2000000000 bps to 98302618816.68% in 2025, then surged by 100 bps to 0.6% in 2026.
- Business Quant data shows HYFT's Operating Margin at 0.6% in Q1 2026, 98302618816.68% in Q4 2025, and 154.19% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Operating Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | - |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | - |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | - |
| 10 | MindWalk Holdings | 166.20 Mn | 156.06 Mn | 1.78 | -0.60% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jan 31, 2026 | -0.60% |
| Oct 31, 2025 | -98,302,618,816.68% |
| Jul 31, 2025 | -154.19% |
| Apr 30, 2025 | -270.92% |
| Jan 31, 2025 | -911.25% |
| Oct 31, 2024 | 0.00% |
| Jul 31, 2024 | -197.09% |
| Apr 30, 2024 | -345.72% |
| Jan 31, 2024 | -53.69% |
| Oct 31, 2023 | -49.15% |
| Jul 31, 2023 | -71.18% |
| Apr 30, 2023 | -153.82% |
| Jan 31, 2023 | -88.57% |
| Oct 31, 2022 | 0.00% |
| Jul 31, 2022 | -0.21% |
| Apr 30, 2022 | -81.83% |
| Jan 31, 2022 | -89,449.64% |
| Oct 31, 2021 | -98.59% |
| Jul 31, 2021 | -75.54% |
| Apr 30, 2021 | -63.54% |